A Multiple-dose, Randomized, Double-blind, Placebo-controlled, Active-Comparator, Parallel Study to Investigate the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Subjects
Latest Information Update: 18 Aug 2023
At a glance
- Drugs Avacopan (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Haemolytic uraemic syndrome; Hidradenitis suppurativa; IgA nephropathy; Membranoproliferative glomerulonephritis
- Focus Adverse reactions
- Sponsors Amgen
- 18 Aug 2023 New trial record